(Q37661510)

21 August 2017

1 reference

title

A comparative review of the lipoglycopeptides: oritavancin, dalbavancin, and telavancin (English)

1 reference

21 August 2017

Michael T Guskey

1

1 reference

21 August 2017

Brian T Tsuji

series ordinal

2

1 reference

21 August 2017

language of work or name

English

0 references

publication date

1 January 2010

1 reference

21 August 2017

1 reference

21 August 2017

volume

30

1 reference

21 August 2017

issue

1

1 reference

21 August 2017

page(s)

80-94

1 reference

Emergence of vancomycin resistance in Staphylococcus aureus. Glycopeptide-Intermediate Staphylococcus aureus Working Group

21 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.30.1.80

Bad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of America

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.30.1.80

The gene cluster for the biosynthesis of the glycopeptide antibiotic A40926 by nonomuraea species

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.30.1.80

Glycopeptides in clinical development: pharmacological profile and clinical perspectives.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.30.1.80

Mechanism of action of oritavancin and related glycopeptide antibiotics

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.30.1.80

Semi-synthetic glycopeptide antibacterials

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.30.1.80

Telavancin, a multifunctional lipoglycopeptide, disrupts both cell wall synthesis and cell membrane integrity in methicillin-resistant Staphylococcus aureus

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.30.1.80

Activity of dalbavancin tested against Staphylococcus spp. and beta-hemolytic Streptococcus spp. isolated from 52 geographically diverse medical centers in the United States

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.30.1.80

Antistaphylococcal activity of LBM415, a new peptide deformylase inhibitor, compared with those of other agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.30.1.80

Comparative surveillance study of telavancin activity against recently collected gram-positive clinical isolates from across the United States

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.30.1.80

In vitro activities of dalbavancin and 12 other agents against 329 aerobic and anaerobic gram-positive isolates recovered from diabetic foot infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.30.1.80

Spectrum and potency of dalbavancin tested against 3322 Gram-positive cocci isolated in the United States Surveillance Program (2004).

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.30.1.80

Comparative in vitro activity of telavancin (TD-6424), a rapidly bactericidal, concentration-dependent anti-infective with multiple mechanisms of action against Gram-positive bacteria

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.30.1.80

In vitro activity of telavancin against resistant gram-positive bacteria

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.30.1.80

Antistaphylococcal activity of dalbavancin, an experimental glycopeptide

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.30.1.80

Comparative activity of telavancin against isolates of community-associated methicillin-resistant Staphylococcus aureus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.30.1.80

Worldwide assessment of dalbavancin activity and spectrum against over 6,000 clinical isolates

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.30.1.80

Dalbavancin activity against selected populations of antimicrobial-resistant Gram-positive pathogens

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.30.1.80

In vitro activities of LY333328 and comparative agents against nosocomial gram-positive pathogens collected in a 1997 global surveillance study

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.30.1.80

Oritavancin--an investigational glycopeptide antibiotic

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.30.1.80

Factors influencing broth microdilution antimicrobial susceptibility test results for dalbavancin, a new glycopeptide agent

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.30.1.80

In vitro activity of TD-6424 against Staphylococcus aureus

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.30.1.80

In vitro activities of the new semisynthetic glycopeptide telavancin (TD-6424), vancomycin, daptomycin, linezolid, and four comparator agents against anaerobic gram-positive species and Corynebacterium spp

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.30.1.80

Pharmacokinetics of oritavancin in plasma and skin blister fluid following administration of a 200-milligram dose for 3 days or a single 800-milligram dose

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.30.1.80

Population pharmacokinetic analysis of dalbavancin, a novel lipoglycopeptide

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.30.1.80

Tissue penetration of telavancin after intravenous administration in healthy subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.30.1.80

Telavancin penetration into human epithelial lining fluid determined by population pharmacokinetic modeling and Monte Carlo simulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.30.1.80

The pharmacokinetic and pharmacodynamic properties of vancomycin

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.30.1.80

Multiple-dose pharmacokinetics of intravenous telavancin in healthy male and female subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.30.1.80

Pharmacokinetics, serum inhibitory and bactericidal activity, and safety of telavancin in healthy subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.30.1.80

Tolerability, pharmacokinetics, and serum bactericidal activity of intravenous dalbavancin in healthy volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.30.1.80

Pharmacokinetics, safety, and tolerability of ascending single intravenous doses of oritavancin administered to healthy human subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.30.1.80

In vivo pharmacodynamic activity of the glycopeptide dalbavancin

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.30.1.80

Effect of growth phase and pH on the in vitro activity of a new glycopeptide, oritavancin (LY333328), against Staphylococcus aureus and Enterococcus faecium

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.30.1.80

Vancomycin allergy presenting as fever of unknown origin

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.30.1.80

Pharmacodynamics in the study of drug resistance and establishing in vitro susceptibility breakpoints: ready for prime time

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.30.1.80

Pharmacodynamics of Oritavancin (LY333328) in a Neutropenic-Mouse Thigh Model of Staphylococcus aureus Infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.30.1.80

Pharmacodynamics of telavancin (TD-6424), a novel bactericidal agent, against gram-positive bacteria

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.30.1.80

The post-antibiotic effect

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.30.1.80

Dalbavancin compared with vancomycin for prevention of Staphylococcus aureus colonization of devices in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.30.1.80

Telavancin: in vitro activity against staphylococci in a biofilm model

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.30.1.80

In vitro activity of LY333328 (oritavancin) against Gram-positive aerobic cocci and synergy with ciprofloxacin against enterococci

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.30.1.80

Assessment by time-kill methodology of the synergistic effects of oritavancin in combination with other antimicrobial agents against Staphylococcus aureus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.30.1.80

Antibacterial susceptibility of a vancomycin-resistant Staphylococcus aureus strain isolated at the Hershey Medical Center

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.30.1.80

Bactericidal activity and resistance development profiling of dalbavancin

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.30.1.80

Effect of LY333328 against vancomycin-resistant Enterococcus faecium in a rat central venous catheter-associated infection model

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.30.1.80

Experimental study of LY333328 (oritavancin), alone and in combination, in therapy of cephalosporin-resistant pneumococcal meningitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.30.1.80

Activity of LY333328 in experimental meningitis caused by a Streptococcus pneumoniae strain susceptible to penicillin

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.30.1.80

Activity and diffusion of LY333328 in experimental endocarditis due to vancomycin-resistant Enterococcus faecalis

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.30.1.80

Activity of LY333328 combined with gentamicin in vitro and in rabbit experimental endocarditis due to vancomycin-susceptible or -resistant Enterococcus faecalis

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.30.1.80

Efficacy of telavancin in a murine model of pneumonia induced by methicillin-susceptible Staphylococcus aureus

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.30.1.80

Efficacy of telavancin (TD-6424), a rapidly bactericidal lipoglycopeptide with multiple mechanisms of action, in a murine model of pneumonia induced by methicillin-resistant Staphylococcus aureus

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.30.1.80

Efficacy of telavancin against penicillin-resistant pneumococci and Staphylococcus aureus in a rabbit meningitis model and determination of kinetic parameters

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.30.1.80

Efficacy of telavancin in the treatment of experimental endocarditis due to glycopeptide-intermediate Staphylococcus aureus

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.30.1.80

Efficacy of Telavancin in a rabbit model of aortic valve endocarditis due to methicillin-resistant Staphylococcus aureus or vancomycin-intermediate Staphylococcus aureus

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.30.1.80

Once-weekly dalbavancin versus standard-of-care antimicrobial regimens for treatment of skin and soft-tissue infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.30.1.80

Efficacy and safety of weekly dalbavancin therapy for catheter-related bloodstream infection caused by gram-positive pathogens

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.30.1.80

Randomized, double-blind comparison of once-weekly dalbavancin versus twice-daily linezolid therapy for the treatment of complicated skin and skin structure infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.30.1.80

Telavancin versus standard therapy for treatment of complicated skin and soft-tissue infections due to gram-positive bacteria

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.30.1.80

Telavancin versus standard therapy for treatment of complicated skin and skin structure infections caused by gram-positive bacteria: FAST 2 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.30.1.80

Telavancin versus vancomycin for the treatment of complicated skin and skin-structure infections caused by gram-positive organisms

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.30.1.80

Microbiologic characterization of isolates from a dalbavancin clinical trial for catheter-related bloodstream infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.30.1.80

21 January 2018

Identifiers

DOI

10.1592/PHCO.30.1.80

1 reference

21 August 2017

1 reference